Anti-CD20 rechallenge with ofatumumab in relapsed/refractory splenic marginal zone lymphoma: the MORE trial

Blood Adv. 2022 Sep 27;6(18):5356-5359. doi: 10.1182/bloodadvances.2022007138.
No abstract available

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / therapeutic use
  • Antigens, CD20
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell*
  • Lymphoma*
  • Neoplasm Recurrence, Local

Substances

  • Antibodies, Monoclonal, Humanized
  • Antigens, CD20
  • ofatumumab